AstraZeneca and San Francisco-based Algen Biotechnologies have entered a strategic collaboration worth up to $555 million, leveraging Algen’s AI-powered AlgenBrain platform that integrates single-cell CRISPR gene editing with artificial intelligence. This partnership targets the discovery of new immunology drug targets by decoding gene regulation and disease associations at single-cell resolution. The alliance exemplifies growing adoption of AI tools to accelerate target identification and drug development in complex therapeutic areas.